Results of a Second Year of Therapy with the 12-Month Histrelin Implant for the Treatment of Central Precocious Puberty

Background. Gonadotropin releasing hormone analogs (GnRHas) are standard of care for central precocious puberty (CPP). The histrelin subcutaneous implant is safe and effective in the treatment of CPP for one year. Objective. The study evaluates a second year of therapy in children with CPP who recei...

Descripción completa

Detalles Bibliográficos
Autores principales: Rahhal, Samar, Clarke, William L., Kletter, Gad B., Lee, Peter A., Neely, E. Kirk, Reiter, Edward O., Saenger, Paul, Shulman, Dorothy, Silverman, Lawrence, Eugster, Erica A.
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2009
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2777002/
https://www.ncbi.nlm.nih.gov/pubmed/19956699
http://dx.doi.org/10.1155/2009/812517

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2777002/
https://www.ncbi.nlm.nih.gov/pubmed/19956699
http://dx.doi.org/10.1155/2009/812517

Ejemplares similares